Tag: Ipsen
Ipsen: more reviews
By Claude Leguilloux Published on 04/05/2024 at 10:39 a.m. (Boursier.com) — Ipsen falls back by 2% to…
Ipsen: global licensing agreement with Sutro Biopharma
(CercleFinance.com) – Ipsen announces the signing of an exclusive global licensing agreement with Sutro Biopharma for STRO-003, an antibody-small molecule conjugate (ADC) currently entering its final stages of preclinical development.…
Ipsen: signature of an exclusive agreement with Sutro Biopharma
(AOF) – Ipsen and Sutro Biopharma announced the signing of an exclusive worldwide licensing agreement for STRO-003. Ipsen obtains exclusive global rights to develop and commercialize STRO-003, an antibody-small molecule…
Ipsen: global licensing agreement with Sutro Biopharma – 04/02/2024 at 08:18
(CercleFinance.com) – Ipsen announces the signing of an exclusive global licensing agreement with Sutro Biopharma for STRO-003, an antibody-small molecule conjugate (ADC) currently entering its final stages of preclinical development.…
Ipsen: the right dosage?
By Claude Leguilloux Published on 02/16/2024 at 10:24 a.m. Ipsen camped on 105 euros this Friday, while the group announced growth in total sales…
Ipsen: FDA approval for the therapeutic regimen including Onivyde, a potential new first-line reference treatment in metastatic pancreatic adenocarcinoma
By Claude Leguilloux Published on 02/14/2024 at 7:27 a.m. (Boursier.com) — Ipsen announces that the American authorities (Food…
Ipsen: UBS reiterates its purchase advice
(CercleFinance.com) – UBS reiterates its buy advice on the stock with a price target of E145, which represents an upside potential of 41%. ‘We recognize the likely increase in competition…
Ipsen: Consolidated net income stands at €647.2 million
By Claude Leguilloux Published on 02/08/2024 at 08:24 a.m. (Boursier.com) — Ipsen announces growth in the Group’s total…
Video – David Loew (CEO of Ipsen): “The stock has risen 50% in 3 years so our strategy is working!”
On the occasion of the publication of Ipsen’s annual results, David Loew, general director of the pharmaceutical laboratory, was the guest of the Ecorama program on February 8, 2024, presented…
Ipsen in sharp decline after its downgrade by Jefferies
(AOF) – Ipsen is among the biggest decliners in the SBF120 this morning after its downgrade by Jefferies. The broker went from Buy to Hold with a price target lowered…
Ipsen at half mast: Jefferies downgrades its recommendation
(AOF) – Ipsen recorded one of the biggest falls in the SBF120, penalized by the downgrade by Jefferies. The broker went from Buy to Hold with a price target lowered…
Ipsen: a gain of 50%…
By Christophe Voisin Published on 09/29/2023 at 4:09 p.m. Pharmaceuticals. In a troubled period, managers are regaining a taste for low-risk projects such as…